Clinical Trials Logo

Filter by:
NCT ID: NCT01137812 Completed - Clinical trials for Diabetes Mellitus, Type 2

The CANTATA-D2 Trial (CANagliflozin Treatment And Trial Analysis - DPP-4 Inhibitor Second Comparator Trial)

Start date: July 2010
Phase: Phase 3
Study type: Interventional

The purpose of this study is to evaluate the efficacy and safety of canagliflozin compared with sitagliptin in patients with type 2 diabetes mellitus who are receiving treatment with metformin and sulphonylurea and have inadequate glycemic (blood sugar) control.

NCT ID: NCT01137734 Completed - Clinical trials for Mitral Valve Insufficiency

CARDINAL Adjustable Annuloplasty Ring System For Treatment of Mitral Regurgitation

Start date: March 2010
Phase: N/A
Study type: Interventional

Annuloplasty device for repair of mitral valve regurgitation with option to adjust device post implant off pump, to optimize correction of mitral regurgitation. Unlike conventional annuloplasty ring, the Cardinal system offers the clinician the opportunity to make adjustments after weaning from cardiopulmonary bypass. Adjustability is expected to reduce the number of patients leaving the operating room with residual regurgitation after mitral valve repair.

NCT ID: NCT01137708 Completed - Healthy Clinical Trials

CP-690,550 And Oral Contraception Drug-Drug Interaction Study

Start date: June 2010
Phase: Phase 1
Study type: Interventional

This study is designed to assess whether co-administration of CP-690,550 and oral contraceptives will effect the metabolism of the oral contraceptives in healthy volunteers.

NCT ID: NCT01137682 Completed - Acromegaly Clinical Trials

Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly

PAOLA
Start date: July 19, 2010
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of pasireotide LAR 40 and 60 mg versus octreotide LAR or lanreotide ATG in patients with inadequately controlled acromegaly.

NCT ID: NCT01135966 Completed - COPD Clinical Trials

Resistance Training in Patients With Chronic Obstructive Lung Disease (COPD): Whole Body Vibration Versus Conventional Resistance Training

REWORK
Start date: April 2010
Phase: Phase 3
Study type: Interventional

Pulmonary rehabilitation has been emerged as a recommended standard of care for patients with chronic lung disease based on a growing body of scientific evidence. A set of evidence-based guidelines were published in American College of Chest Physicians (ACCP) and the American Association of Cardiovascular and Pulmonary Rehabilitation (AACVPR). Since then, the published literature in pulmonary rehabilitation has increased substantially, and other societies have published important statements about pulmonary rehabilitation (eg, the American Thoracic Society and the European Respiratory Society). In patients with COPD, there is a strong scientific basis for implementing conventional resistance training (CRT) in addition to endurance training. Endurance training, such as walking, is a key component of pulmonary rehabilitation and improves in exercise tolerance and muscular endurance. However, this type of training may not reverse muscle weakness or atrophy. For that reason, strength training seems to be the optimum training modality to increase muscle mass and strength. Recently, Whole-Body-Vibration (WBV) training has been promoted as an alternative for resistance training on multigym equipment. In WBV training, the subject stands on a platform that generates vertical sinusoidal vibration, during which static and dynamic exercises can be performed. The present study is conducted to provide an answer on the following question: will a resistance training program, such as the whole body vibration, be even effective than a conventional resistance training program in patients with COPD.

NCT ID: NCT01135797 Completed - Clinical trials for Peripheral Arterial Occlusive Disease

Retrospective Safety Survey In Patients Included In NV1FGF Clinical Trials

TALISMAN S
Start date: June 2010
Phase: N/A
Study type: Observational

The objective of this study is to collect retrospectively long term safety data in patients who have participated in the previous phase I-II trials conducted with the compound.

NCT ID: NCT01135745 Completed - Clinical trials for Obsessive Compulsive Disorder

Deep Brain Stimulation for Obsessive Compulsive Disorder (OCD PMCF)

Start date: April 2010
Phase: Phase 4
Study type: Interventional

The purpose of the study is to monitor the safety and performance of Reclaim® Deep Brain Stimulation (DBS) Therapy in patients with chronic, severe, treatment-resistant Obsessive Compulsive Disorder.

NCT ID: NCT01135459 Completed - Clinical trials for Systemic Lupus Erythematosus

A Study to Evaluate the Efficacy and Safety of CEP-33457 in Participants With Systemic Lupus Erythematosus (SLE)

Start date: June 24, 2010
Phase: Phase 2
Study type: Interventional

The primary objective of this study is to evaluate the efficacy of a 200 micrograms (mcg) dose of CEP-33457 compared with placebo in participants with active systemic lupus erythematosus (SLE) as assessed by the proportion of participants achieving a combined clinical response using the SLE responder index (SRI) at Week 24.

NCT ID: NCT01135225 Completed - Clinical trials for Coronary Artery Disease

Non-inferiority Trial to Assess the Safety and Performance of the Evolution Coronary Stent

Evolve
Start date: July 2010
Phase: N/A
Study type: Interventional

The purpose of the EVOLVE Trial is to assess the safety and performance of the everolimus-eluting Evolution stent for the treatment of a de novo atherosclerotic lesion of up to 28 mm in length in a native coronary artery 2.25 mm to 3.5 mm in diameter. The safety and performance of two different drug release rate formulations of the Evolution Stent will be compared to the commercially available PROMUS (TM) Element (TM) drug-eluting stent.

NCT ID: NCT01134055 Completed - Clinical trials for Macular Degeneration

Dose Ranging Study of Pazopanib to Treat Neovascular Age-Related Macular Degeneration

Start date: June 1, 2010
Phase: Phase 2
Study type: Interventional

The purpose of this study is to determine the safety and efficacy of different dosage regimens of pazopanib eye drops for the treatment of neovascular age-related macular degeneration.